Get the Stockscreener App
2.95
0.85%
0.025
Pre-market:
2.97
0.02
+0.68%
Mannkind Corp stock is traded at $2.95, with a volume of 7.05M.
It is up +0.85% in the last 24 hours and down -48.96% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$2.925
Open:
$2.96
24h Volume:
7.05M
Relative Volume:
1.55
Market Cap:
$905.86M
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
59.00
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-15.71%
1M Performance:
-48.96%
6M Performance:
-44.76%
1Y Performance:
-42.72%
1-Day Range:
$2.865
$3.01
1-Week Range:
$2.83
$3.72
52-Week Range:
$2.83
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.95 | 898.18M | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Finviz
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
MannKind (NASDAQ:MNKD) Sets New 1-Year LowHere's What Happened - MarketBeat
MannKind (NASDAQ: MNKD) CFO adds 5,000 shares via stock purchase plan - Stock Titan
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan - Stock Titan
MannKind (MNKD) director reports vesting of 45,025 performance-based stock options - Stock Titan
MannKind (MNKD) CEO gains stock and option vesting on milestones - Stock Titan
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade - MarketBeat
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook By Investing.com - Investing.com Canada
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook - Investing.com
RBC Capital downgrades MannKind stock rating on royalty concerns By Investing.com - Investing.com Canada
RBC Capital downgrades MannKind stock rating on royalty concerns - Investing.com
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance - Markets Mojo
MannKind Corporation (MNKD): A Bull Case Theory - Finviz
MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About MannKind Corp (MNKD) - GuruFocus
MNKD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5 - GuruFocus
What's Going On With MannKind Stock Friday? - Benzinga
MNKD: HC Wainwright & Co. Lowers Price Target to $8.00 | MNKD St - GuruFocus
Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance
MNKD Should I Buy - Intellectia AI
Why MannKind Stock Tumbled on Thursday - Yahoo Finance
MannKind at Oppenheimer Conference: Strategic Insights for 2026 - Investing.com
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Earnings call transcript: MannKind Q4 2025 results show mixed performance By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead - Investing.com
Earnings call transcript: MannKind Q4 2025 results show mixed performance - Investing.com
MannKind hits 52-week low on Q4 earnings miss (MNKD:NASDAQ) - Seeking Alpha
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 - ChartMill
Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M - marketscreener.com
MANNKIND ($MNKD) Releases Q4 2025 Earnings - Quiver Quantitative
MannKind: Fourth Quarter Earnings Overview - Bitget
MannKind: Q4 Earnings Snapshot - marketscreener.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corporation Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Caledonian Record
MannKind Earnings Review: Q4 Summary - Benzinga
MannKind (NASDAQ:MNKD) Reaches New 1-Year LowShould You Sell? - MarketBeat
United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook - simplywall.st
MNKD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MNKD MannKind (NASDAQ): Shares slide 36.82% to $3.50 pre-earnings, catalyst to watch - Meyka
MannKind Corp stock hits 52-week low at $3.36 By Investing.com - Investing.com Australia
MannKind stock plummets after partner United Therapeutics unveils new 'category killer product' - MSN
MannKind (MNKD) Shares Plummet Amid United Therapeutics Announcement - GuruFocus
MannKind (MNKD) Sees Stock Drop After Competitor's Product Devel - GuruFocus
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):